HealthEquity (NASDAQ:HQY) Issues FY 2027 Earnings Guidance

Posted by Brian Himes on May 30th, 2026

HealthEquity (NASDAQ:HQY – Get Free Report) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided EPS guidance of 2.880-2.950 for the period, compared to the consensus EPS estimate of 4.470. The company issued revenue guidance of -.

HealthEquity Stock Performance

Shares of HQY stock opened at $87.99 on Friday. The company’s fifty day simple moving average is $83.44 and its 200-day simple moving average is $86.77. The company has a quick ratio of 3.27, a current ratio of 3.27 and a debt-to-equity ratio of 0.45. The firm has a market cap of $7.38 billion, a PE ratio of 32.96, a P/E/G ratio of 1.65 and a beta of 0.19. HealthEquity has a 12 month low of $72.76 and a 12 month high of $116.65.

HealthEquity (NASDAQ:HQY – Get Free Report) last announced its quarterly earnings data on Thursday, May 28th. The company reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.13. The business had revenue of $354.64 million for the quarter, compared to analyst estimates of $352.02 million. HealthEquity had a net margin of 17.25% and a return on equity of 14.61%. The business’s quarterly revenue was up 7.2% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 2.880-2.950 EPS. Equities research analysts expect that HealthEquity will post 3.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have issued reports on HQY shares. Deutsche Bank Aktiengesellschaft upped their price target on shares of HealthEquity from $120.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. KeyCorp reaffirmed an “overweight” rating on shares of HealthEquity in a research report on Tuesday. Royal Bank Of Canada upped their price target on shares of HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research report on Friday. JPMorgan Chase & Co. dropped their price target on shares of HealthEquity from $129.00 to $123.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Finally, Barclays dropped their price target on shares of HealthEquity from $118.00 to $110.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $112.36.

Check Out Our Latest Report on HQY

Key HealthEquity News

Here are the key news stories impacting HealthEquity this week:

Positive Sentiment: HealthEquity beat Q1 FY27 expectations, reporting $1.24 EPS on $354.6 million in revenue, with revenue up 7.2% year over year and net income up 29%; the company also raised its full-year outlook. HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance
Positive Sentiment: The company expanded its share repurchase authorization by $1 billion, which can support per-share earnings and signals confidence in future cash generation. HealthEquity outlines fiscal 2027 revenue of $1.41B-$1.42B while expanding share repurchase authorization by $1B
Positive Sentiment: Royal Bank of Canada raised its price target on HealthEquity to $108 from $100 and reiterated an outperform rating, implying further upside from current levels. Benzinga
Neutral Sentiment: Earnings call coverage and transcript articles highlighted management commentary, but did not add materially new investor information beyond the reported results and guidance. HealthEquity, Inc. (HQY) Q1 2027 Earnings Call Transcript
Neutral Sentiment: Short-interest data showed no meaningful change to the stock’s trading backdrop. HealthEquity (NASDAQ:HQY) – Get Free Report

Hedge Funds Weigh In On HealthEquity

Institutional investors and hedge funds have recently modified their holdings of the stock. Sivia Capital Partners LLC acquired a new position in shares of HealthEquity in the second quarter valued at $306,000. Advisory Services Network LLC acquired a new position in shares of HealthEquity in the third quarter valued at $207,000. iSAM Funds UK Ltd increased its holdings in shares of HealthEquity by 81.3% in the fourth quarter. iSAM Funds UK Ltd now owns 2,239 shares of the company’s stock valued at $205,000 after purchasing an additional 1,004 shares during the last quarter. Merit Financial Group LLC grew its stake in shares of HealthEquity by 8.9% in the third quarter. Merit Financial Group LLC now owns 2,112 shares of the company’s stock valued at $200,000 after acquiring an additional 172 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in HealthEquity by 14.3% during the fourth quarter. Parallel Advisors LLC now owns 1,387 shares of the company’s stock worth $127,000 after acquiring an additional 173 shares during the period. 99.55% of the stock is currently owned by institutional investors and hedge funds.

HealthEquity Company Profile

(Get Free Report)

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.